Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study

被引：0
|
作者：
Bibian M. E. Tullemans
Sanne L. N. Brouns
Frauke Swieringa
Siamack Sabrkhany
Franchette W. P. J. van den Berkmortel
Natascha A. J. B. Peters
Peter de Bruijn
Stijn L. W. Koolen
Johan W. M. Heemskerk
Maureen J. B. Aarts
Marijke J. E. Kuijpers
机构：
[1] Maastricht University,Cardiovascular Research Institute Maastricht, Department of Biochemistry
[2] Synapse Research Institute,Cardiovascular Research Institute Maastricht, Department of Physiology
[3] Maastricht University,Department of Medical Oncology
[4] Zuyderland Medical Centre,Department of Internal Medicine
[5] Sint Jans Gasthuis,Department of Medical Oncology, Erasmus MC Cancer Institute
[6] Erasmus University Medical Centre,Thrombosis Expertise Centre, Heart and Vascular Centre
[7] Department of Pharmacy,undefined
[8] Erasmus University Medical Centre,undefined
[9] Department of Medical Oncology,undefined
[10] Maastricht University Medical Centre+,undefined
[11] Maastricht University Medical Centre,undefined
来源：
BMC Cancer | / 22卷
关键词：
Platelet count; Platelet aggregation; Sunitinib; Tyrosine kinase inhibitor; Renal cell carcinoma; cancer; Patients; Plasma; Serum; Bleeding;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 41 条
  • [21] Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
    Proskorovsky, Irina
    Benedict, Agnes
    Negrier, Sylvie
    Bargo, Danielle
    Sandin, Rickard
    Ramaswamy, Krishnan
    Desai, Jigar
    Cappelleri, Joseph C.
    Larkin, James
    BMC CANCER, 2018, 18
  • [22] Genome-wide association meta-analysis identifies novel variants that correlate with efficacy outcomes in sunitinib-treated patients with metastatic renal cell carcinoma
    Diekstra, M.
    Swen, J.
    van der Zanden, L.
    Vermeulen, S.
    Boven, E.
    Mathijssen, R. H.
    Oskarsdottir, A.
    Oosterwijk, E.
    Cambon-Thomsen, A.
    Castellano, D.
    Fritsch, A.
    Garcia-Donas, J.
    Rodriguez-Antona, C.
    Jaehde, U.
    Rafnar, T.
    Stefansson, K.
    Bohringer, S.
    Kubo, M.
    Kiemeney, L.
    Guchelaar, H-J.
    ANNALS OF ONCOLOGY, 2021, 32 : S703 - S704
  • [23] Quality of life (QoL) among patients with renal cell carcinoma (RCC) treated with pazopanib versus sunitinib in the COMPARZ study
    Cella, David
    Hackshaw, Michelle Denise
    Diaz, Jose
    Huang, Chun
    Deen, Keith C.
    Crescenzo, Rocco
    Motzer, Robert John
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [24] A retrospective multicenter study of MSKCC poor-prognosis patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib
    Heng, D. Y.
    Elson, P.
    Golshayan, A. R.
    Warren, M. A.
    Kollmannsberger, C.
    Chi, K. N.
    Cheng, T.
    North, S. A.
    Garcia, J. A.
    Bukowski, R. M.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study
    Desar, I. M. E.
    ter Voert, E. G. W.
    Hambrock, Th.
    van Asten, J. J. A.
    van Spronsen, D. J.
    Mulders, P. F. A.
    Heerschap, A.
    van der Graaf, W. T. A.
    van Laarhoven, H. W. M.
    van Herpen, C. M. L.
    CANCER IMAGING, 2012, 11 (01) : 259 - 265
  • [26] C-Reactive Protein Levels and Survival Following Cytoreductive Nephrectomy in 118 Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Study
    Xu, Wen-Hao
    Wang, Jun
    Huo, Da-Zhu
    Yin, Guo-Cai
    Cao, Da-Long
    Shi, Guo-Hai
    Qu, Yuan-Yuan
    Ye, Ding-Wei
    Zhang, Hai-Liang
    MEDICAL SCIENCE MONITOR, 2019, 25 : 8984 - 8994
  • [27] Changes in Circulating Pro-Angiogenic Cytokines, other than VEGF, before Progression to Sunitinib Therapy in Advanced Renal Cell Carcinoma Patients
    Porta, Camillo
    Paglino, Chiara
    Imarisio, Ilaria
    Ganini, Carlo
    Sacchi, Lucia
    Quaglini, Silvana
    Giunta, Vania
    De Amici, Mara
    ONCOLOGY, 2013, 84 (02) : 115 - 122
  • [28] Relation between lactate dehydrogenase (LDH) during two first cycles in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU)
    Medioni, J.
    Arakelian, N.
    Fournier, L.
    Helley, D.
    Thiam, R.
    Banu, E.
    Cuenod, C.
    Oudard, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial
    Bilen, Mehmet Asim
    Zurita, Amado J.
    Ilias-Khan, Nasreen A.
    Chen, Hsiang-Chun
    Wang, Xuemei
    Kearney, Alper Y.
    Hodges, Sherie
    Jonasch, Eric
    Huang, Shixia
    Khakoo, Aarif Yusuf
    Tannir, Nizar M.
    ONCOLOGIST, 2015, 20 (10): : 1140 - 1148
  • [30] Circulating cytokines and angiogenic factors (CAFs) in patients with advanced non-clear cell renal cell carcinoma treated with sunitinib: Results from a phase II clinical trial
    Bilen, Mehmet Asim
    Zurita, Amado J.
    Ilias-Khan, Nasreen A.
    Chen, Hsiang-Chun
    Wang, Xuemei
    Hodges, Sherie
    Lim, Zita D.
    Jonasch, Eric
    Khakoo, Aarif Yusuf
    Tannir, Nizar M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
12345